BioNTech Shares Gain Momentum on Promising Clinical Trial and Acquisition

Positive clinical trial results for a key oncology asset and the near-completion of a strategic acquisition are providing a potential catalyst for BioNTech SE, whose stock has been trading near its 52-week low.

BioNTech has secured 81.74% of CureVac NV's shares, moving the landmark takeover toward closure. The settlement for these shares is scheduled for December 15, 2025, with an additional acceptance period running until December 18.

This transaction significantly bolsters BioNTech's position in the mRNA technology field. The company gains access to over 1,000 additional mRNA-related patents and expanded manufacturing capabilities. Furthermore, the deal consolidates the competitive landscape by integrating a former rival, substantially strengthening BioNTech's market leadership.

Impressive Phase 3 Data for Oncology Candidate

New data from the PRESERVE-003 Phase 3 trial demonstrates compelling efficacy for the investigational antibody gotistobart in treating previously treated squamous non-small cell lung cancer. The therapy showed a 54% reduction in the risk of death compared to standard chemotherapy with docetaxel.

Key metrics from the initial analysis include:

• 12-Month Overall Survival Rate: 63.1% for patients on gotistobart versus 30.3% for those on docetaxel.
• Median Overall Survival: Not yet reached at 14.5 months, compared to 10 months for the control group.
• Hazard Ratio: 0.46 (p-value 0.0102).

The U.S. Food and Drug Administration has already granted Fast Track designation to gotistobart for metastatic lung cancer. The crucial second part of the study is already underway with approximately 500 patients globally, with initial data anticipated in 2026.

Should investors sell immediately? Or is it worth buying BioNTech?

Analyst Sentiment Remains Largely Positive

Market analysts maintain a generally constructive outlook on the equity. Current consensus shows ten analysts recommending a "buy," four advising investors to "hold," and one suggesting "sell." The average price target stands at $137.75, representing a significant premium to recent trading levels.

Several firms have recently reiterated or adjusted their targets. Berenberg Bank raised its price objective to $155, while Jefferies views $151 as a fair valuation. Analysts at HC Wainwright and Morgan Stanley also maintain positive ratings, albeit with adjusted earnings expectations for 2025.

Strong Financial Foundation and Pipeline

BioNTech's financial position remains robust, with liquid resources totaling €16.7 billion. The company recently received a $1.5 billion payment from Bristol Myers Squibb as part of a partnership for the antibody candidate pumitamig.

For the 2025 fiscal year, revenue is projected to be between €2.6 billion and €2.8 billion. Research and development expenditures are planned in the range of €2.0 billion to €2.2 billion.

Beyond gotistobart, the company is advancing pumitamig for breast and lung cancers. In a Phase 2 trial for triple-negative breast cancer, the candidate achieved a 72% objective response rate. Results from several additional clinical studies are expected over the coming months.